Amir Hadanny, MD and Shai Efrati, MD of The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (the largest hyperbaric treatment center worldwide) in Be'er Ya'akov, Israel has begun a new clinical trial to study the treatment of...
Jean-Eric Blatteau, MD, PhD of Sainte Anne Military Teaching Hospital in Toulon, France has begun a new clinical trial to study the treatment of COVID-19 patients using Hyperbaric Oxygen Therapy. Several patients with hypoxaemic SARS-CoV2 pneumonia were...
Dr. Jeffery S Kuo is the Lead Investigator of the latest clinical trial studying the treatment of COVID-19 patients with Hyperbaric Oxygen Therapy. The study will be based out of Ochsner Medical Center in New Orleans, Louisiana. Patients who meet...
April 2, 2020, Dr. David Lee posted a new clinical trial on the NIH Clinical Trials website to study the use of Hyperbaric Oxygen Therapy (HBOT) to treat COVID-10. The study is listed as "Not Recruiting Yet," but has an estimated completion date of July 2020. ...
Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning. The most commonly associated complication of HBOT is middle ear barotrauma (MEB) which occurs when the eustachian tube does not allow air to enter the middle ear space to equalize the pressure between the ambient environment and the inner ear. Patients experiencing MEB usually feel pressure or pain in their ear(s). The spectrum of symptoms ranges from sensation of ear fullness and muffled hearing to severe pain, vertigo and tympanic membrane rupture. HBOT has not been studied. The investigators plan to perform a randomized double blind placebo control trial to determine if pseudoephedrine is effective in decreasing the rate of MEB during HBOT.
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure. We explore a treatment administered in a randomized clinical trial that could prevent ICU admission and reduce mortality. The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the inflammatory response.
Abstract Ketone bodies (KBs), comprising β-hydroxybutyrate, acetoacetate and acetone, are a set of fuel molecules serving as an alternative energy source to glucose. KBs are mainly produced by the liver from fatty acids during periods of fasting, and prolonged or...
Middle ear barotrauma (MEB) is the most common complication during hyperbaric oxygen therapy
(HBOT). Though Valsalva and Toynbee maneuvers have been proposed to prevent MEB, still some
patients discontinue HBOT due to severe otalgia, hemorrhage or perforation of tympanic
membrane associated with HBOT. Currently, there is no optimal prophylactic management for MEB
associated with HBOT. The aim of this protocol is to investigate the efficacy of
self-acupressure therapy on MEB associated with HBOT.
Abstract: Persistent postconcussion syndrome (PPCS) after mild traumatic brain injury (mTBI) is a significant public health and military problem for which there is limited treatment evidence. The aim of this study was to determine whether forty 150 kPa hyperbaric...
Currently, Hyperbaric Oxigen (HBO) is a widely used treatment for several conditions. There
are 14 indications for HBO, officially recognized by the Undersea and Hyperbaric Medical
Society (UHMS), but research is discovering other interesting applications.
HBO plays an important role in enhancing antioxidant defense mechanisms by increasing radical
oxygen species (ROS) and nitric oxide species (NOS). This controlled oxidative stress has
been shown to stop the vicious circle of inflammation – damage – hypoxia already seen in
several diseases. Increased neoangiogenesis has been demonstrated at pressures of 2
atmospheres absolute (ATA), while effects helping ischemic tissues need pressures between 2.5
and 2.8 ATA to develop.
During sports activities, metabolism generates waste products – mostly CO2, lactic acid, but
also ROS. HBO could be useful in modulating antioxidant mechanisms and helping cells in the
recovery after training and sportive competitions.
The authors hypothesize that:
1. HBO can reduce oxidative stress in healthy professional athletes
2. HBO can ameliorate the lactic acid clearance after a maximal exercise
3. HBO at low pressures (L-HBO at 1.45 ATA) is at least comparable to conventional HBO (at
2.5 ATA) in reducing oxidative stress and ameliorating lactic acid clearance after a
maximal exercise.
The Authors will include healthy athletes. These will be randomly assigned to a control
group, a L-HBO group, or a HBO group. The Authors will assess oxidative stress changes and
lactic acid clearance (testing it after a maximal exercise) before and after 20 L-HBO/HBO
treatments, and after 2 months after the end of treatments.